Thrombosis Resource Center Editorial Programs

 
 
  • 20 Years of Progress in Secondary Stroke Prevention   Dr Diener discusses some of the milestones in the last 20 years for secondary stroke prevention.
  • Hypertension Affects VTE Too   Dr Goldhaber discusses some changes we may see in the incidence of MI, stroke, DVT, and PE if the medical community were to accept and adopt the new blood pressure targets studied in SPRINT.
  • Benefit vs Risk of Extended Anticoagulation After PE   Does 24 months of anticoagulation therapy after unprovoked PE result in better outcomes than 6 months of treatment? Dr Andrew Shorr analyzes the PADIS-PE trial.
  • The Psychological Toll of VTE   A recent study serves as a reminder to ask patients with VTE about their emotional health as well as their physical well-being.
  • Overdiagnosis of Pulmonary Embolism by CT   Overall, PE is underdiagnosed, but Dr Goldhaber reviews a paper on overdiagnosis and provides suggestions on how to avoid it.
  • Reversing New Oral Anticoagulants: New Agents on the Horizon   Dr Goldhaber interviews Dr Pollack about the REVERSE-AD study evaluating a new dabigatran reversal agent and what the future holds for other NOAC reversal agents.
  • Anticoagulation With Dabigatran: When to Worry How do renal impairment, advanced age, low body weight, and drug interactions affect dabigatran?
  • ESC Debating NOACs vs Warfarin for PE: A Boxing Match Dr Walton-Shirley takes on the role of sports reporter as she gives a blow-by-blow account of a debate on treating pulmonary embolism.
  • ESC Is the CHA2DS2-Vasc Useful Beyond Atrial Fibrillation? Dr John Mandrola looks into the science of why anticoagulant drugs in some patients with heart failure might be successful at reducing the risk of stroke.
  • Radiology's Overdiagnosis Problem Dr Saurabh Jha guest-edited an issue of Academic Radiology devoted to the topic of overdiagnosis. Medscape asks him why radiologists should be concerned about this topic.
  • D-dimer Disappoints   Dr Goldhaber reviews a Canadian study on the use of D-dimer testing to predict recurrent VTE.
  • Anticoagulation in Patients with Cancer and VTE   Dr Goldhaber reviews an analysis of the patients with cancer in the pivotal VTE trials of new oral anticoagulants.
  • GARFIELD-AF: Room for Improvement in Both Men and Women   Are women at risk for AF less likely to receive oral anticoagulation than men? Dr Goldhaber reviews data from a global registry.
  • HRS Potpourri With Mandrola and Turakhia   Dr Mandrola asks Dr Turakhia about NOAC adherence, the limits of ICD appropriate use criteria, using ICD data for research, and whether cardiologists are better than PCPs in managing patients with AF.
  • Pulmonary-Embolism Response Team: Not Just for the Big Boys   Dr Seth Bilazarian reviews the benefits of a PERT program at his community hospital and suggests other practitioners start one.
  • London Bridge Is Falling Down   Insights on bridging therapy when anticoagulation has to be interrupted, from the ORBIT-AF registry.
  • Total Joint Patients Prefer VTE Prophylaxis Device A new study confirms that the ActiveCare mobile compression device is equivalent to warfarin in preventing VTEs in total joint patients, reducing adverse events and increasing patient satisfaction.
  • Acute PE: Increased Role for Cardiologists   Drs Goldhaber and Bilazarian discuss the cardiologist's increasing role in treating PE with the advent of NOACs.
  • Fondaparinux for DVT Prevention in Moderate Renal Impairment Should this factor Xa inhibitor be dose-reduced in moderate renal impairment?
  • GARFIELD-AF: Anticoagulation in the Real World   Sam Goldhaber and John Camm discuss the international GARFIELD-AF registry, expected to bring a wealth of data about the use of anticoagulation in patients with atrial fibrillation.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.